Hear Sue share how IncyteCARES—a patient support program for eligible adults taking Jakafi® (ruxolitinib)—connected her with information regarding coverage and educational support to help her throughout her journey with Jakafi.
Sue: I'm Sue. I'm a mother of three boys. I've been married for 26 years and I run a home daycare.
Onscreen text: Sue was first prescribed Jakafi® (ruxolitinib) in 2012.
Sue: My hematologist told me about this new drug called Jakafi…
Sue: So when I started Jakafi I received a lot of information about it. I heard about this program called IncyteCARES that helps with copays on Facebook so I called the number. IncyteCARES sent out packages and all kinds of materials…
Narrator: IncyteCARES is the one-stop destination specifically tailored for people prescribed Jakafi® (ruxolitinib).
Onscreen text: The one-stop destination specifically tailored for people prescribed Jakafi® (ruxolitinib)
Sue: So at first I really didn’t need their help, but then my copay changed drastically. So I contacted them and got copay assistance to a very manageable level and then I learned about the other programs that they offer.
*Terms and conditions apply.
Narrator: Jakafi patients, like Sue, come to rely on IncyteCARES team members to help get them started on Jakafi, provide access to educational support resources, and explain coverage and financial assistance options that may even include zero-dollar copays for eligible patients.
Onscreen text: Patient support and resources to help manage daily life
Narrator: From their first prescription, IncyteCARES supports patients with both a welcome kit and resources for managing daily life.
Sue: I received all kinds of information packets in the mail. They’re available online or, you know, they-they mailed the packets to me. I still get them. They offer emotional support. You can contact nurses directly.
Narrator: In fact, IncyteCARES offers a range of resources designed to help support and inform conversations with Healthcare Professionals, to help patients maintain a positive outlook, and to provide symptom tracking and daily medicine monitoring, as well as connections to transportation providers, and more.
Sue: IncyteCARES just provides you knowledge and support. With a rare disease it’s, it’s nice to have someplace to go to, to talk and learn.
Onscreen text and narrator: IncyteCARES is an assistance program for eligible patients and their caregivers that can provide support when starting Jakafi® (ruxolitinib) and throughout the treatment journey.
Narrator: Connect with IncyteCARES today!
Visit IncyteCARES.com or call 1-855-452-5234.
Onscreen text: Connect with IncyteCARES today!
Visit: IncyteCARES.com or call:1-855-452-5234, Monday through Friday, 8 am–8 pm ET
Onscreen text: This video is sponsored by Incyte Corporation.
Jakafi and the Jakafi logo are registered trademarks of Incyte.
© 2020, Incyte Corporation. MAT-INC-00518 09/20
Register for the Incyte Mentor Program and connect with another patient taking Jakafi.
Register for the Incyte Mentor
Program and connect with another
patient taking Jakafi.
Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.
Jakafi is used to treat adults with certain types of myelofibrosis.
Jakafi is used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.
Jakafi is also used to treat adults and children 12 years of age and older with chronic GVHD who have taken one or two types of treatments and they did not work well enough.
Jakafi can cause serious side effects, including:
Low blood counts: Jakafi® (ruxolitinib) may cause low platelet, red blood cell, and white blood cell counts. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.
Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.
Cancer: Some people have had certain types of non-melanoma skin cancers during treatment with Jakafi. Your healthcare provider will regularly check your skin during your treatment with Jakafi. Tell your healthcare provider if you develop any new or changing skin lesions during treatment with Jakafi.
Increases in cholesterol: You may have changes in your blood cholesterol levels during treatment with Jakafi. Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking Jakafi, and as needed.
Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis: Get emergency help right away if you have any symptoms of a heart attack or stroke while taking Jakafi, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back, severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw, pain or discomfort in your arms, back, neck, jaw, or stomach, shortness of breath with or without chest discomfort, breaking out in a cold sweat, nausea or vomiting, feeling lightheaded, weakness in one part or on one side of your body, slurred speech
Increased risk of blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with Jakafi, including: swelling, pain, or tenderness in one or both legs, sudden, unexplained chest or upper back pain, shortness of breath or difficulty breathing
Possible increased risk of new (secondary) cancers: People who take another JAK inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers. People who smoke or who smoked in the past have an added risk of new cancers.
The most common side effects of Jakafi include: for certain types of myelofibrosis (MF) and polycythemia vera (PV) – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; for acute GVHD – low platelet counts, low red or white blood cell counts, infections, and swelling; and for chronic GVHD – low red blood cell or platelet counts and infections including viral infections.
These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Call your doctor for medical advice about side effects.
Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had low white or red blood cell counts, have or had tuberculosis (TB) or have been in close contact with someone who has TB, had shingles (herpes zoster), have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had cancer, are a current or past smoker, had a blood clot, heart attack, other heart problems or stroke, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.
Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.
Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
You may also report side effects to Incyte Medical Information at 1-855-463-3463.